interferon beta-1a + methotrexate

**Interferon beta-1a + methotrexate** is a combination therapy composed of two pharmaceuticals: interferon beta-1a, a recombinant protein used primarily as an immunomodulatory agent in multiple sclerosis, and methotrexate, a small molecule antimetabolite with anti-inflammatory and immunosuppressive properties[1][3][4][5]. Interferon beta-1a works by modulating the immune system and decreasing inflammation, likely by reducing antigen presentation, T cell activation, and cytokine expression. Methotrexate acts by inhibiting dihydrofolate reductase (DHFR), reducing DNA synthesis in rapidly dividing cells, and increasing extracellular adenosine, which provides anti-inflammatory effects by acting on adenosine receptors and inhibiting T cell proliferation[2][4]. This combination has been studied in relapsing-remitting multiple sclerosis (RRMS), particularly in patients not optimally responsive to interferon beta monotherapy[1][3]. The available data suggest additive efficacy in reducing MRI lesion activity and possible reduction in relapse rate, with a side effect profile consistent with the known tolerability of both agents, such as nausea[1][3].

Brand names

Avonex

Other names

MTX + AvonexMethotrexate + AvonexAvonex Combination Trial regimen